{
  "main_header": {
    "sid": 981287,
    "name": "Bacil Pharma",
    "stock_name": "Bacil Pharma",
    "full_name": "Bacil Pharma Ltd",
    "name_url": "stocks-analysis/bacil-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "40.00",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "40.00",
    "mcapval": "55.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 524516,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 49,
    "indexname": "",
    "isin": "INE711D01018",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "949 ",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/bacil-pharma-981287-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "How has been the historical performance of Bacil Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-bacil-pharma-3703447",
        "imagepath": "",
        "date": "2025-11-15 00:00:05",
        "description": "Answer:\nThe historical performance of Bacil Pharma shows a consistent lack of revenue generation over the years, with net sales and other operating income remaining at zero from March 2019 to March 2025. Despite this, the company has seen a significant improvement in its profit metrics, achieving a profit after tax of 0.40 crore in March 2025, a notable recovery from losses in previous years, including a loss of 3.86 crore in March 2022. The total expenditure has decreased from 3.92 crore in March 2022 to 0.25 crore in March 2025, indicating improved cost management. The company's total assets have increased dramatically from 1.27 crore in March 2024 to 25.55 crore in March 2025, primarily driven by a rise in non-current investments. \n\nBreakdown:\nBacil Pharma's financial history reveals a persistent absence of sales and operating income from March 2019 through March 2025, with total operating income consist..."
      },
      {
        "title": "How has been the historical performance of Bacil Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-bacil-pharma-3699332",
        "imagepath": "",
        "date": "2025-11-13 23:32:17",
        "description": "Answer:\nThe historical performance of Bacil Pharma shows a consistent trend of zero net sales and other operating income from March 2019 to March 2025. The total operating income remained at zero throughout this period, with the only notable expense being employee costs, which increased slightly from 0.05 crore in March 2021 to 0.14 crore in March 2025. The total expenditure, excluding depreciation, peaked at 3.92 crore in March 2022 but has since decreased to 0.25 crore by March 2025. Operating profit (PBDIT) was negative across all years, with a significant loss of 3.92 crore in March 2022, improving to a positive 0.41 crore in March 2025. Profit after tax also turned positive in March 2025 at 0.40 crore, a significant recovery from losses in previous years. The company's total assets increased dramatically from 1.27 crore in March 2024 to 25.55 crore in March 2025, primarily due to a rise in non-current ..."
      }
    ],
    "total": 4,
    "sid": "981287",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/bacil-pharma-981287"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "13-Jan-2026",
      "details": "Compliances-Certificate under Reg.74(5) of SEBI (DP) Regulations2018",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "30-Dec-2025",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Khem Sum Apparels Overseas Ltd",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "29-Dec-2025",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Suman P Shah",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

How has been the historical performance of Bacil Pharma?

2025-11-15 00:00:05

Answer: The historical performance of Bacil Pharma shows a consistent lack of revenue generation over the years, with net sales and other operating income remaining at zero from March 2019 to March 2025. Despite this, the company has seen a significant improvement in its profit metrics, achieving a profit after tax of 0.40 crore in March 2025, a notable recovery from losses in previous years, including a loss of 3.86 crore in March 2022. The total expenditure has decreased from 3.92 crore in March 2022 to 0.25 crore in March 2025, indicating improved cost management. The company's total assets have increased dramatically from 1.27 crore in March 2024 to 25.55 crore in March 2025, primarily driven by a rise in non-current investments. Breakdown: Bacil Pharma's financial history reveals a persistent absence of sales and operating income from March 2019 through March 2025, with total operating income consist...

Read More

How has been the historical performance of Bacil Pharma?

2025-11-13 23:32:17

Answer: The historical performance of Bacil Pharma shows a consistent trend of zero net sales and other operating income from March 2019 to March 2025. The total operating income remained at zero throughout this period, with the only notable expense being employee costs, which increased slightly from 0.05 crore in March 2021 to 0.14 crore in March 2025. The total expenditure, excluding depreciation, peaked at 3.92 crore in March 2022 but has since decreased to 0.25 crore by March 2025. Operating profit (PBDIT) was negative across all years, with a significant loss of 3.92 crore in March 2022, improving to a positive 0.41 crore in March 2025. Profit after tax also turned positive in March 2025 at 0.40 crore, a significant recovery from losses in previous years. The company's total assets increased dramatically from 1.27 crore in March 2024 to 25.55 crore in March 2025, primarily due to a rise in non-current ...

Read More

View All News